The $1.75 billion deal for Alios BioPharma marks the first acquisition in some time for Johnson & Johnson. Alios is working on treatments for viral diseases.
By DAVID GELLES, New York Times
Tue, 09/30/2014 - 7:24am
The $1.75 billion deal for Alios BioPharma marks the first acquisition in some time for Johnson & Johnson. Alios is working on treatments for viral diseases.